Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Health Sciences Acquisitions Corporation 2 (HSAQ) Stock Forecast & Price Prediction United States | NASDAQ | |
$4.66
-0.14 (-2.92%)Did HSAQ Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if HSAQ is one of their latest high-conviction picks.
HSAQ has shown a year-to-date change of 12.3% and a 1-year change of -11.6%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for HSAQ. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for HSAQ.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
The following stocks are similar to HSAQ based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Health Sciences Acquisitions Corporation 2, a SPAC sponsored by RTW Investments, completed its business combination on January 26, 2023.
The completion of the business combination may enhance market confidence and liquidity for the company, potentially impacting stock performance and investor sentiment positively.
Medtronic is collaborating to develop BackBeat Cardiac Neuromodulation Therapyโข for hypertension treatment in cardiac pacemaker patients.
The collaboration with Medtronic signals innovation in hypertension treatment, potentially increasing market share and revenue for companies involved, impacting stock performance positively.
Analyst forecasts for Health Sciences Acquisitions Corporation 2 (HSAQ) are not currently available. The stock is trading at $4.66.
Analyst ratings for HSAQ are not currently available. The stock is currently trading at $4.66. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for HSAQ are not currently available. The stock is trading at $4.66.
N/A
Price targets from Wall Street analysts for HSAQ are not currently available. The stock is trading at $4.66.
Price targets from Wall Street analysts for HSAQ are not currently available. The stock is trading at $4.66.
Analyst ratings for HSAQ are not currently available. The stock is trading at $4.66.
Stock price projections, including those for Health Sciences Acquisitions Corporation 2, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.